Cargando…
The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
Defects in DNA repair pathways are emerging hallmarks of cancer. Accurate DNA repairs and replications are essential for genomic stability. Cancer cells require residual DNA repair capabilities to repair the damage from replication stress and genotoxic anti-tumor agents. Defective DNA repair also pr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300834/ https://www.ncbi.nlm.nih.gov/pubmed/35875146 http://dx.doi.org/10.3389/fonc.2022.935593 |
_version_ | 1784751292139175936 |
---|---|
author | Wang, Ziyi Jia, Renxiang Wang, Linlin Yang, Qiwei Hu, Xiaohai Fu, Qiang Zhang, Xinyu Li, Wenya Ren, Yi |
author_facet | Wang, Ziyi Jia, Renxiang Wang, Linlin Yang, Qiwei Hu, Xiaohai Fu, Qiang Zhang, Xinyu Li, Wenya Ren, Yi |
author_sort | Wang, Ziyi |
collection | PubMed |
description | Defects in DNA repair pathways are emerging hallmarks of cancer. Accurate DNA repairs and replications are essential for genomic stability. Cancer cells require residual DNA repair capabilities to repair the damage from replication stress and genotoxic anti-tumor agents. Defective DNA repair also promotes the accumulation of genomic changes that eventually lead to tumorigenesis, tumor progression, and therapeutic resistance to DNA-damaging anti-tumor agents. Rad51 recombinase is a critical effector of homologous recombination, which is an essential DNA repair mechanism for double-strand breaks. Rad51 has been found to be upregulated in many malignant solid tumors, and is correlated with poor prognosis. In multiple tumor types, Rad51 is critical for tumor metabolism, metastasis and drug resistance. Herein, we initially introduced the structure, expression pattern of Rad51 and key Rad51 mediators involved in homologous recombination. Additionally, we primarily discussed the role of Rad51 in tumor metabolism, metastasis, resistance to chemotherapeutic agents and poly-ADP ribose polymerase inhibitors. |
format | Online Article Text |
id | pubmed-9300834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93008342022-07-22 The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target Wang, Ziyi Jia, Renxiang Wang, Linlin Yang, Qiwei Hu, Xiaohai Fu, Qiang Zhang, Xinyu Li, Wenya Ren, Yi Front Oncol Oncology Defects in DNA repair pathways are emerging hallmarks of cancer. Accurate DNA repairs and replications are essential for genomic stability. Cancer cells require residual DNA repair capabilities to repair the damage from replication stress and genotoxic anti-tumor agents. Defective DNA repair also promotes the accumulation of genomic changes that eventually lead to tumorigenesis, tumor progression, and therapeutic resistance to DNA-damaging anti-tumor agents. Rad51 recombinase is a critical effector of homologous recombination, which is an essential DNA repair mechanism for double-strand breaks. Rad51 has been found to be upregulated in many malignant solid tumors, and is correlated with poor prognosis. In multiple tumor types, Rad51 is critical for tumor metabolism, metastasis and drug resistance. Herein, we initially introduced the structure, expression pattern of Rad51 and key Rad51 mediators involved in homologous recombination. Additionally, we primarily discussed the role of Rad51 in tumor metabolism, metastasis, resistance to chemotherapeutic agents and poly-ADP ribose polymerase inhibitors. Frontiers Media S.A. 2022-07-07 /pmc/articles/PMC9300834/ /pubmed/35875146 http://dx.doi.org/10.3389/fonc.2022.935593 Text en Copyright © 2022 Wang, Jia, Wang, Yang, Hu, Fu, Zhang, Li and Ren https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Ziyi Jia, Renxiang Wang, Linlin Yang, Qiwei Hu, Xiaohai Fu, Qiang Zhang, Xinyu Li, Wenya Ren, Yi The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target |
title | The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target |
title_full | The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target |
title_fullStr | The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target |
title_full_unstemmed | The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target |
title_short | The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target |
title_sort | emerging roles of rad51 in cancer and its potential as a therapeutic target |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300834/ https://www.ncbi.nlm.nih.gov/pubmed/35875146 http://dx.doi.org/10.3389/fonc.2022.935593 |
work_keys_str_mv | AT wangziyi theemergingrolesofrad51incanceranditspotentialasatherapeutictarget AT jiarenxiang theemergingrolesofrad51incanceranditspotentialasatherapeutictarget AT wanglinlin theemergingrolesofrad51incanceranditspotentialasatherapeutictarget AT yangqiwei theemergingrolesofrad51incanceranditspotentialasatherapeutictarget AT huxiaohai theemergingrolesofrad51incanceranditspotentialasatherapeutictarget AT fuqiang theemergingrolesofrad51incanceranditspotentialasatherapeutictarget AT zhangxinyu theemergingrolesofrad51incanceranditspotentialasatherapeutictarget AT liwenya theemergingrolesofrad51incanceranditspotentialasatherapeutictarget AT renyi theemergingrolesofrad51incanceranditspotentialasatherapeutictarget AT wangziyi emergingrolesofrad51incanceranditspotentialasatherapeutictarget AT jiarenxiang emergingrolesofrad51incanceranditspotentialasatherapeutictarget AT wanglinlin emergingrolesofrad51incanceranditspotentialasatherapeutictarget AT yangqiwei emergingrolesofrad51incanceranditspotentialasatherapeutictarget AT huxiaohai emergingrolesofrad51incanceranditspotentialasatherapeutictarget AT fuqiang emergingrolesofrad51incanceranditspotentialasatherapeutictarget AT zhangxinyu emergingrolesofrad51incanceranditspotentialasatherapeutictarget AT liwenya emergingrolesofrad51incanceranditspotentialasatherapeutictarget AT renyi emergingrolesofrad51incanceranditspotentialasatherapeutictarget |